Licenses and Other Agreements - Additional Information (Details) - USD ($)
|
1 Months Ended |
3 Months Ended |
41 Months Ended |
Jan. 31, 2020 |
Nov. 30, 2017 |
Mar. 31, 2021 |
Mar. 31, 2020 |
Mar. 31, 2021 |
| License Agreements [Line Items] |
|
|
|
|
|
| Research and development |
|
|
$ 22,320,000
|
$ 11,449,000
|
|
| Purchase obligation, year 2022 through 2023 |
|
|
14,000,000.0
|
|
$ 14,000,000.0
|
| Purchase obligation, year 2024 |
|
|
37,000,000.0
|
|
37,000,000.0
|
| Purchase obligation, year 2025 through 2031 |
|
|
48,000,000.0
|
|
48,000,000.0
|
| Duke University |
|
|
|
|
|
| License Agreements [Line Items] |
|
|
|
|
|
| Sale of licensed products or services |
|
|
0
|
|
|
| Fees payment |
|
|
300,000
|
|
|
| Nonroyalty payment received |
|
|
1,000,000.0
|
|
|
| Research and development |
|
|
0
|
0
|
|
| Wacker |
|
|
|
|
|
| License Agreements [Line Items] |
|
|
|
|
|
| Research and development |
|
|
100,000
|
100,000
|
|
| Viamet Pharmaceuticals Holdings, LLC |
|
|
|
|
|
| License Agreements [Line Items] |
|
|
|
|
|
| Research and development |
|
|
0
|
$ 100,000
|
|
| License agreement upfront payment |
$ 100,000
|
|
|
|
|
| Maximum | Achievement Of Clinical Development And Regulatory Milestones | Duke University |
|
|
|
|
|
| License Agreements [Line Items] |
|
|
|
|
|
| Potential milestones payment |
|
|
2,200,000
|
|
|
| Maximum | Commercial Milestones | Duke University |
|
|
|
|
|
| License Agreements [Line Items] |
|
|
|
|
|
| Potential milestones payment |
|
|
400,000
|
|
|
| Maximum | Commercial Milestones | Viamet Pharmaceuticals Holdings, LLC |
|
|
|
|
|
| License Agreements [Line Items] |
|
|
|
|
|
| Potential milestones payment |
142,500,000
|
|
|
|
|
| Maximum | Achievement Of Certain Development And Intellectual Property Milestones | Viamet Pharmaceuticals Holdings, LLC |
|
|
|
|
|
| License Agreements [Line Items] |
|
|
|
|
|
| Potential milestones payment |
$ 5,100,000
|
|
|
|
|
| Minimum | Duke University |
|
|
|
|
|
| License Agreements [Line Items] |
|
|
|
|
|
| Aggregate royalties payment |
|
|
200,000
|
|
|
| MedImmune Limited |
|
|
|
|
|
| License Agreements [Line Items] |
|
|
|
|
|
| Milestone payment |
|
|
|
|
$ 3,000,000.0
|
| MedImmune Limited | Maximum | Achievement Of Clinical Development And Regulatory Milestones |
|
|
|
|
|
| License Agreements [Line Items] |
|
|
|
|
|
| Potential milestones payment |
|
|
$ 15,000,000.0
|
|
|
| MedImmune Limited | Maximum | Commercial Milestones |
|
|
|
|
|
| License Agreements [Line Items] |
|
|
|
|
|
| Potential milestones payment |
|
$ 50,000,000.0
|
|
|
|